The repair FDA calls manufacturing
FDA's final guidance on servicing and remanufacturing turns on one question: did the repair return a device to its original maker's own specifications, or change them? Cross that line, and 21 CFR 820.3's definition of a remanufacturer makes the repairer a device manufacturer — registration, listing, and quality system included.
By Connor Griggs — Regulatory & Quality Strategist
A hospital biomed replaces a worn seal in an infusion pump, using the original maker’s own part and procedure. A third-party servicer swaps in a compatible sensor board the original maker never validated. Both events are “repair.” FDA’s final guidance on servicing and remanufacturing, issued May 10, 2024, exists to explain why only one of them stays outside the definition of manufacturing.
Two acts, one dividing question
The guidance defines servicing as repair or preventive and routine maintenance of a finished device, after distribution, done for the purpose of returning it to the safety and performance specifications established by the original equipment manufacturer and to meet its original intended use. Remanufacturing is processing, conditioning, renovating, repackaging, restoring, or any other act done to a finished device that significantly changes its performance, its safety specifications, or its intended use. The dividing question is not how invasive the work looked. It is whether the device that comes back out is still built to the same specifications as the one that went in.
The definition was already in the regulation
FDA’s guidance is, by its own cover page, nonbinding — a recommendation, not a rule. The rule was already there. 21 CFR 820.3 defines a remanufacturer as any person who processes, conditions, renovates, repackages, restores, or does any other act to a finished device that significantly changes the finished device’s performance or safety specifications, or intended use — language the 2024 guidance repeats almost word for word. A remanufacturer is a device manufacturer under that regulation, full stop, whether or not it ever reads FDA’s guidance on the subject. What the guidance adds is illustration: examples of changes FDA considers significant — a new sterilization method, revised reprocessing instructions, a changed control mechanism, operating principle, or energy type — that a servicer can check its own work against before FDA does.
Six years from question to guidance
This did not appear from nowhere. The FDA Reauthorization Act of 2017 required FDA to post a report on the quality, safety, and effectiveness of device servicing; the resulting May 2018 report found the evidence insufficient to justify new servicing-specific regulation, and committed instead to clarifying the boundary between servicing and remanufacturing that already existed in 820.3. A draft guidance followed in June 2021; the final version posted almost three years after that. The underlying rule did not move in the interval. What changed is how much a servicer can now know about where FDA draws the line before an inspection tells them.
Servicing returns a device to specifications someone else already set. Remanufacturing writes new ones — and the moment it does, the servicer is the manufacturer of record for that device, whether it intended to take on the role or not.
What crossing the line actually attaches
A firm FDA or a court concludes has remanufactured a device inherits the ordinary obligations of a device manufacturer for it: establishment registration and listing, the quality system regulation, complaint handling, medical device reporting, and — if the change is the kind that affects safety or effectiveness — a new premarket submission before the device goes back into service. None of that is contingent on intent. A well-meaning independent service organization that substitutes an unvalidated part believing it equivalent has still, under 820.3, remanufactured the device if the substitution changes performance or safety specifications — the guidance’s recommendations are what help it avoid finding that out from an inspector first.
The practice
Nothing about this guidance creates a new public record to watch. The determination happens inside a servicer’s own quality system, and the only place it reliably surfaces publicly is the same one CDRH manufacturing violations of every other kind surface in — a warning letter, naming the firm, dated and posted like any other. FDA Radar’s warning-letter pipeline reads the subject line as a taxonomy of violation categories, per what we monitor and how often, and a remanufacturing determination would read there exactly like any other quality-system or registration finding — nothing marks it as this specific theory rather than another. For an OEM with a service network, or a device firm relying on third-party refurbishers in its supply chain, that makes the guidance worth reading directly rather than waiting to see it in an enforcement record: whether a specific repair, substitution, or refurbishment crosses into remanufacturing is a determination for a regulatory professional looking at the actual change, not a call this post is making. This is regulatory intelligence and method, never regulatory advice about any device’s service history.
Primary sources
- Federal Register — Remanufacturing of Medical Devices; Guidance for Industry, Entities That Perform Servicing or Remanufacturing, and Food and Drug Administration Staff; Availability
- FDA — Remanufacturing and Servicing Medical Devices
- eCFR — 21 CFR 820.3, Definitions
- FDA — Reports and Plans Mandated by FDARA
- FDA Radar — what we monitor and how often
Regulatory intelligence, not regulatory advice. This post describes method and published FDA records as of its date; decisions about a specific device belong with your regulatory professional.